Zoetis Expands Osteoarthritis Pain Management Portfolio with Lenivia Launch in Canada and EU — Zoetis Inc.

Event summary

Zoetis launched Lenivia® (izenivetmab injection), a long-acting monoclonal antibody therapy for canine osteoarthritis pain, in Canada and the EU on July 15, 2026.
Lenivia offers up to three months of pain management with a single subcutaneous injection, backed by a nine-month European field study showing sustained pain reduction.
The therapy targets nerve growth factor (NGF) at a different site than existing anti-NGF monoclonal antibodies, providing an alternative treatment option.
Zoetis aims to address the growing demand for senior pet care, as osteoarthritis affects up to 40% of dogs and is becoming more prevalent with advances in veterinary care.

The big picture

Zoetis's launch of Lenivia underscores the company's commitment to addressing unmet needs in canine osteoarthritis pain management. As pets live longer due to advancements in veterinary care, the demand for effective and convenient long-term pain solutions is growing. This strategic move positions Zoetis to capture a larger share of the expanding senior pet care market, leveraging its established portfolio and scientific expertise.

What we're watching

Market Adoption: The pace at which veterinarians and pet owners adopt Lenivia will determine its commercial success, particularly given the competitive landscape of existing OA pain treatments.
Regulatory Compliance: Zoetis's ability to navigate varying regulatory requirements across Canada and EU member states could impact the therapy's widespread availability and approval in other regions.
Pipeline Integration: How Zoetis integrates Lenivia into its broader osteoarthritis pain management portfolio, including Rimadyl, Trocoxil, and Librela, will shape its long-term strategy in this therapeutic area.